Caldera, close to global breakthrough on new prostate cancer test, seeks new investors

Caldera, close to global breakthrough on new prostate cancer test, seeks new investors
By Jonathan Underhill May 18 (BusinessDesk) - Caldera Health, a New Zealand biotech company working on a gene-sequencing replacement for the world's most widely used prostate cancer test, is seeking new investors to complete a $2 million capital raising to finish clinical studies and put the research in front of potential commercial partners. Auckland-based Caldera has attracted $5.93 million of investment since being incorporated in 2009, made up of $5.4 million from investors including New Image Group founder Graeme Clegg, Stephen Tinda...